Literature DB >> 11408803

Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas.

H Azechi1, N Nishida, Y Fukuda, T Nishimura, M Minata, H Katsuma, M Kuno, T Ito, T Komeda, R Kita, R Takahashi, K Nakao.   

Abstract

p16, cyclin D1 and retinoblastoma protein (pRB) regulate G1 to S transition and are commonly targeted in various cancers. However, few studies have simultaneously examined all components of the p16/cyclin D1/pRB pathway (RB pathway) in hepatocellular carcinoma (HCC). To clarify the role of the disruption of the RB pathway in HCC, we analyzed p16, pRB and cyclin D1 in 47 HCCs. Inactivation of p16 was detected in 30 of 47 HCCs (64%) by Western blot analysis and significantly correlated with hypermethylation of the promoter of this gene. pRB expression was found to be absent in 13 of 47 HCCs (28%) by immunohistochemistry. We found that 38 of 47 HCCs (81%) contained at least one inactivation in either pRB or p16. Furthermore, there was a significant inverse correlation between p16 and pRB inactivation (p = 0.041). Overexpression of cyclin D1 was detected in 5 of 47 HCCs (11%) by immunohistochemistry. The cases with cyclin D1 overexpression exhibited an advanced clinicopathological appearance and also contained inactivation of pRB and/or p16. These findings suggest that inactivation of pRB and/or p16 is a major event in human hepatocarcinogenesis, while cyclin D1 overexpression may confer additional growth advantages to the tumor in addition to pRB and/or p16 inactivation in HCC. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408803     DOI: 10.1159/000058531

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  39 in total

1.  Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma.

Authors:  Chiara Braconi; Nicola Valeri; Takayuki Kogure; Pierluigi Gasparini; Nianyuan Huang; Gerard J Nuovo; Luigi Terracciano; Carlo M Croce; Tushar Patel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma.

Authors:  Sirintip Boonjaraspinyo; Thidarut Boonmars; Sasithorn Kaewkes; Porntip Laummaunwai; Somchai Pinlaor; Watchalin Loilome; Puangrat Yongvanit; Zhiliang Wu; Anucha Puapairoj; Vajarabhongsa Bhudhisawasdi
Journal:  Pathol Oncol Res       Date:  2011-07-13       Impact factor: 3.201

Review 3.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 4.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

5.  Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran.

Authors:  S J Moghaddam; E N Haghighi; S Samiee; N Shahid; A R Keramati; S Dadgar; M R Zali
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

6.  Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control.

Authors:  Christopher A Reed; Christopher N Mayhew; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

7.  Expression and significance of tumor-related genes in HCC.

Authors:  Zi-Li Lü; Dian-Zhong Luo; Jian-Ming Wen
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 8.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

Review 9.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

10.  RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.

Authors:  C A Reed; C N Mayhew; A K McClendon; X Yang; A Witkiewicz; E S Knudsen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.